SHANNON RAY
SCHRADER, M.D.
PREMEDICAL
EDUCATION / EXPERIENCE
COLLEGE:
Bachelor of
Science Degree - Biology, May 1984
MEDICAL
EDUCATION:
Doctor of
Medicine, May 1989
AWARDS:
graduation from medical school
RESIDENCY
COLLEGE:
Family
Medicine;
June 1989 -
June 1992
Chief Resident, 1991 - 1992
AWARDS: Ida and Taylor Pickett Award
- upon graduation
outstanding resident
PROFESSIONAL
SOCIETY MEMBERSHIPS:
American
Medical Association, 1985 - present
Texas
Academy of Family Physicians, 1989 - present
Texas
Medical Association, 1992 - present
Harris
County Medical society, 1992 - present
International
Association of Physicians in AIDS Care
American
VOLUNTEERING: United Way - Big Brothers / Big Sisters
Program, 1984 - 1989
AIDS
Foundation of
Casa Juan
Diego - indigent clinic for Central Americans in
EXAMINATIONS: Part I and Part II - National Boards
FLEX
Examination /
Family
Practice Certification Boards, July 1992, July 1999
PRACTICE: Solo Practitioner,
July 1992 -
December 1993
Southampton
Medical Group, L.C., Partner;
December
1993 – December 2002
The
January
2003 - Present
OTHER
EMPLOYMENT: HospiCenter
of Houston - Home Care Team Physician,
1994 – 1996
1998 - present
Thomas
Street Clinic (
1995 – 2000
Applied Home
Healthcare Hospice – Medical Director
5/1998 –
5/1999
AVES (Amigos Volunteers in Education and Services –
indigent HIV clinic for Latino persons) – Medical Director
1998 – 2001
HOSPITAL
AFFILIATIONS: St. Luke’s Episcopal Hospital
COMMITTEES:
AVES – Board member, 1998 – 2001
Center for AIDS – Medical Advisory Board / Community
Advisory Board
PoWeR (Program for Wellness Restoration) – Advisory Board
VOLUNTEERING: Montrose Clinic - STD / HIV Clinic
SEARCH –
Homeless shelter – medical clinic project
RESEARCH: Medical Director - Montrose
Clinic Research
215
Westheimer
Montrose
Clinic Research– Richmond
August
1995 - present
Investigator
- AmFAR
Community Based Clinical Trials Network
January
1995 - December 1997
Co-Investigator
- The Terry Beirn
Community Programs for Clinical Research on AIDS (CPCRA):
April 2000 -
Present
STATE
LICENSES:
PUBLICATIONS: Arduino RC, Nannini E, Rodrigues-Barradas M, Schrader
S, Allende M, Losso M, Ruxrungtham K, Emery S, Fosdick
L, Tavel J, Davey R, Lana
HC. Meta-Analysis of the CD4 Cell
Response to 3 Doses of Subcutaneous Interleukin-2 (scIL-2) Across 3 Vanguard
Studies. Program & Abstracts of
the 8th Conference on Retrovirus and Opportunistic Infections,
C.Holtzer, F.M.Hecht, M.Swanson, P.Ruane, S.Schrader, C.De Guzman, D.Lapins, J.Stansell, San Francisco General Hosp., San Francisco, CA,
Tower I.D., Los Angeles, CA, Southampton Med. Group, Houston, TX, Clinical
Partners, San Francisco, CA. The Influence of Intensive Medication Adherence Strategies on the
Clinical Outcome of HIV-Infected Patients Taking Protease Inhibitor.
Abstract, 9th European Congress of Clinical Microbiology
and Infectious Diseases,
J.C.Gathe, C.Shapiro,
S.Schrader,
C.Mayberry, T.Dahl, T.Wong.
J.E.Mobley, R.Pollard, S.Schrader, M.Adler, T.Kelleher, C.McLaren, AI454-143
Team. Cooper Green Hosp., Birmingham, AL, University of Texas,
Galveston, TX, Montrose Clinic, Houston, TX, Bristol-Myers Squibb, Wallingford,
CT. Comparison of Once- and Twice- Daily
Dosing of Didanosine in Combination with Stavudine in Treatment-Naïve Patients.
Abstract, 4th International Congress on Drug
Therapy in HIV Infection,
S.Schrader, B.Burkhardt, J.C.Gathe.
J.Gathe, D.F.Piot, S.Schrader, C.C.Mayberry, E.W.Stool, Therapeutic Concepts,
J.A.Hellinger, R.A.Torres, S.Schrader, et al. Safety
and antiretroviral activity of hydroxyurea (HU) with ddI in HIV-infected individuals. Abstract I-127, 37th Interscience
Conference on Antimicrobial Agent and Chemotherapy,
Served as an Investigator on
the Following
Clinical
Research Protocols:
A Pilot Randomized, Double-Blind, Placebo-Controlled,
Parallel Design, Multi-Center Trial to
Evaluate the Effect of Ranitidine on Immunologic Indicators in
Asymptomatic HIV-1 Infected Subjects with
a CD4 Count Between 400 and 700 cells/mm3
NUCA-3002: A Randomized 3TC™, ddC,
Double-Blind (ZDV Open- Labeled) Multicenter Trial to
Evaluate the Safety and Efficacy of 3TC™
(low dose) Administered Concurrently with ZDV, Versus 3TC™ (high dose)
Administered Concurrently with ZDV, Versus ddC Administered
Concurrently with ZDV in the Treatment of HIV-1 Infected,
ZDV-Experienced (> 24 weeks) Patients with CD4 Cell Counts of 100 to 300
cells/mm3
3TCTM Open
Label Program
GS-93-302: A
Phase I/II Study of the Safety and Efficacy of Topical HPMPC
in the Treatment of Condyloma Acuminatum
in Patients with
HIV Infection
GCSF-930101: A Randomized, Controlled, Multicenter
Trial of filgrastim
(Recombinant-methionyl Human Granulocyte Colony Stimulating
Factor) for the Prevention of Grade 4 Neutropenia in Patients with HIV Infection
BIPI 1062A: A Long-term Open-label Trial Assessing
Safety and Tolerance of Chronic Nevirapine
Dosing in HIV-1 Infected Patients
028574PR0003:
A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and
Efficacy of Chronically Administered MDL 28,574A in the
Treatment of HIV-Infected Patients
028574PR0004: A Randomized, Double-Blind
Placebo-Controlled, Dose-Ranging Study of the Safety and
Efficacy of Chronically Administered MDL 28,574A in the
Treatment of HIV-Infected Patients
033-02: A Multiclinic,
Double-Blind, Randomized, Eighteen-Month Study in HIV-1 Seropositive
Patients to Compare the Efficacy and Safety
of MK-639, 800 mg q8h, and Zidovudine, 200 mg q8h, Administered Concomitantly to
MK-639 Alone and Zidovudine Alone
AmFAR CBCTN 06: Trimethoprim Sulfamethoxazole (TMP/SMX) Desensitization Versus
Direct Rechallenge In HIV-Infected Patients Who
Are At High Risk For Pneumocystis Carinii
Pneumonia And Have
Experienced A Previous Adverse Reaction To TMP/SMX
HCRN
Protocol 95-03-L1: A Pilot, Dose Ranging Study to Evaluate the Safety and Activity of Hydroxyurea in HIV Infected Patients
HDI-95-001: A Pilot Open Label Study to Evaluate the
Safety, Tolerance and Activity of Glucocorticoid, Multi-Vitamins, and Amino Acid Dietary
Supplement Regimen for Treating Subjects Infected with the Human
Immunodeficiency Virus (HIV)
AmFAR CBCTN 07: A Phase I/II Open-Label Study of the Safety
and Antiretroviral Activity of Hydroxyurea with ddI in HIV-Infected Individuals
HBY 097 - 2001: A Multicenter, Randomized,
Double-Blinded, Dose-Escalation Study Evaluating the
Safety and Antiretroviral Activity
of HBY 097 vs HBY 097 + AZT in Patients with Asymptomatic
or Mildly Symptomatic HIV Infection
AmFAR CBCTN 08: HIV-RNA (bDNA)
Levels Following Initiation of Lamivudine (3TC) in HIV-Infected
Persons who are Adding 3TC to a Stable
Antiretroviral Regimen
AG1343 – 510: A Phase
I/II Pilot Study of VIRACEPT™ (AG1343) in Combination with Stavudine (d4T)
Versus Stavudine Alone in HIV-Positive Patients
AG1343 - 511: A Phase III Randomized, Double-Blind,
Placebo-Controlled, Study of VIRACEPT™ in Combination with Zidovudine (AZT) +
Lamivudine (3TC) Versus AZT + 3TC Alone in HIV Positive Patients with < 1
Month or No Prior Antiretroviral Treatment
GS-96-408:
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the
Efficacy and Safety of Adefovir Dipivoxil
When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected
Patients With CD4 Cell Counts Between > 200/mm3
AI454-143:
A Randomized, Double-Blind, Study of the Antiviral Activity of Once-Daily and
Twice-Daily Dosing of Didanosine in Combination with Twice-Daily Dosing of
Stavudine in HIV-Infected Subjects
CNAA/B3005:
A Phase III Randomized, Double-Blind, Multicenter Study to Evaluate the Safety
and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected
Antiretroviral Therapy Naive Subjects
001.0012: - Phase III Randomized, Double Blinded,
Placebo Controlled Trial of Recombinant Human Granulocyte-Macrophage
Colony-Stimulating Factor (rhu GM-CSF) in Patients
with Advanced HIV Disease
DMP
266-020: - A Phase III, Double-blind, Placebo-Controlled, Multicenter Study to
Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in
HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy
NZTA4002:
- A Comparison of a Four-drug Regimen Comprised of 141W94, Abacavir (1592U89),
and Combivir™ with a Three-drug Regimen Comprised of Nelfinavir
and Combivir™ in Antiretroviral-Naive, HIV-Infected Subjects
IL-2
Vanguard Protocol: - A Randomized, Open Label, Phase II Study of Subcutaneous
Interleukin-2 (Proleukin®) Plus Antiretroviral Therapy vs. Antiretroviral
Therapy Alone in Patients with HIV Infection and at Least 350 CD4+ Cells/mm3
Protocol
076-02 / CRX 441: - A Multicenter, Open-label, Randomized, 24-Week Study to
Compare the Safety and Activity of Indinavir Sulfate,
800 mg q8h Versus 1200 mg q12h, in HIV-Infected Individuals Having Plasma Viral
RNA Less Than 400 copies/mL, on Concomitant Therapy with 2 Nucleoside Analogue
Reverse Transcriptase Inhibitors (NRTI)
FIP:
98-01-01: - Phase II Trial of FP-21399 in Patients with HIV Infection On Stable Antiviral Therapy Without Complete Viral
Suppression
DMP
266-006: - A 24-Week Phase III Multicenter, Randomized, Open-label Study To
Compare Antiretroviral Activity And Tolerability Of Three Combination Regimens
(DMP 266 + Indinavir, DMP 266 + Zidovudine +
Lamivudine, Indinavir + Zidovudine + Lamivudine) In
HIV-Infected Patients
DMP
266-043: - A Phase II, Open-label, Multicenter Study to Characterize the
Effectiveness and Safety of Efavirenz in Combination with Stavudine and
Lamivudine in Antiretroviral Therapy-Naïve HIV-Infected Patients
AG1036
– An Open Label Study to Assess the Safety and Antiviral Activity of a Three
Drug Regimen Consisting of Nelfinavir, Stavudine and
Efavirenz in HIV-Infected Patients
RIGHT
702 – A Phase I/II Study of the Safety and Antiretroviral Activity of Nine Hydroxyurea Regimens in Combination with ddI and d4T
AG1661-202 – A Randomized, Double-blind, Adjuvant-controlled,
Multicenter, Study to Compare the Virologic and Immunologic Effect of Highly
Active Antiretroviral Therapy (HAART) Plus REMUNE™ Versus HAART Plus Incomplete
Freund’s Adjuvant (IFA) in Antiretroviral-naïve Patients Infected with Human
Immunodeficiency Virus Type 1 (HIV-1)
FTC-301 - A Randomized, Double-Blind, Equivalence Trial
Comparing Emtricitabine to Stavudine within a Triple Drug Combination
Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naïve HIV-1
Infected Patients
EPV20001 - A Phase II/III 48-Week, Randomized, Double-Blind,
Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine
300mg Once Daily vs Lamivudine 150mg BID in
Combination with Zidovudine 300mg BID and Efavirenz 600mg Once Daily in
Antiretroviral-Naïve Adults with HIV-1 Infection
AI424-009 – Safety and Antiviral Activity of a Novel HIV-1
Protease Inhibitor, BMS-232632 in Combination Regimen(s) as Compared to
Reference Combination Regimens in Antiretroviral-experienced HIV-infected
Subjects
ESPRIT Protocol 001 – A Randomized, Open-Label, Phase III,
International Study of Subcutaneous Recombinant IL-2 (Proleukin®) in Patients
with HIV-1 Infection and CD4+ Cell Counts > 300/mm3: Evaluation of
Subcutaneous Proleukin® in a Randomized International Trial (ESPRIT)
APV-401 – Amprenavir (Agenerase™) as a First Protease Inhibitor with Strategies
for Subsequent Therapy
AG1549-508 – A Double-blind, Randomized, Placebo-controlled
Study of AG1549 in Combination with Viracept™ and Two
Nucleoside Reverse Transcriptase Inhibitors in HIV- infected Subjects Who
Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing
Regimen
ESS40001 – A Phase IV, Open-Label, Randomized Study to Compare
the Efficacy and Safety of Epivir®/Ziagen™/Zerit®
(3TC/ABC/d4T) Versus Epivir®/Ziagen™/Sustiva™ (3TC/ABC/EFV)
Versus Epivir®/Ziagen™/Agenerase™/Norvir
(3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who
are Antiretroviral Therapy Naïve
UMD-00-066 – A Phase III, Randomized, Double-Blind,
Placebo-Controlled, Study of Oxymetholone
Administered in Conjunction with Resistance Exercise and Nutritional Counseling
in Adult Males with HIV-Associated Weight Loss
CPCRA 058 – A Randomized, Open-Label Study of the Long-Term
Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART)
Strategies in HAART-Naïve, HIV-Infected Persons
CPCRA 060 – A Prospective Study of Long-Term Clinical,
Virologic, and Immunologic Outcomes in HIV-Infected Individuals
CPCRA 062 – Adherence Strategies Using a Medication Manager
and an Electronic Medication Reminder System for HIV-Infected Patients
Receiving HAART
AI424-034 – A Phase III Study Comparing the Antiviral Efficacy
and Safety of BMS-232632 With Efavirenz; Each in
Combination With Fixed Dose Zidovudine-Lamivudine
CPCRA 064 – A Randomized Study of a Prescribed 4-Month
Structured Treatment Interruption (STI) Followed by Initiation of a New
Antiretroviral Regimen Versus Immediate Initiation of
a New Antiretroviral Regimen In HIV-Infected Patients with Multidrug Resistant
(MDR) Virus
An Open Label, Single Site Salvage Regimen Trial Comparing Crixivan/Norvir Plus Two New Nucleosides Versus Fortovase/Norvir Plus Two New Nucleosides After First
Protease Inhibitor Failure
A Study to Assess the Long-term Antiviral Activity, Safety and
Tolerability of BMS-232632 in Combination Regimens in HIV-infected Subjects Who
Have Completed Participation in Clinical Studies of BMS-232632
AI424-043 – A Randomized, Open-Label Study of the Antiviral
Efficacy and Safety of Atazanavir versus Lopinavir/Ritonavir (LPV/RTV) each in
Combination With Two Nucleosides in Subjects who have Experienced Virologic
Failure With Prior Protease Inhibitor-Containing HAART Regimen(s)
AI424-045 – A Randomized, Open-label Study Of The Antiviral
Efficacy And Safety Of Atazanavir, In Combination With Ritonavir Or Saquinavir, And The Combination Of Lopinavir/Ritonavir Each
With Tenofovir And A Nucleoside In Subjects Who Have Experienced Virologic
Failure
CPCRA 065 – A Large, Simple Trial Comparing Two strategies for
Management of Anti-Retroviral Therapy (The SMART Study)
ACH443-006 - A Phase 2 Trial of 4 Weeks of ACH-126,443 in
Comparison With Continued Lamivudine in Stable Triple antiretroviral
combination Therapy in HIV-Infected Subjects With
Modestly Detectable Viral Load
AI455135 - A Phase IIIB, Open-Label, Randomized, Multicenter
Study Switching HIV-1 Infected Subjects with a Viral Load of < 50 Copies/mL
on a BID or More frequent Initial HAART Regimen to a Once Daily Regimen
Including Stavudine XR, Lamivudine, and Efavirenz
ACH443-902 - An Open-Label Treatment Protocol to Provide
Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored
Studies in HIV Infection
AI424-077 - Atazanavir (BMS-232632) for HIV Infected
Individuals Completing Atazanavir Clinical Trials: An Extended Access Study
AI424-067 - A Phase IIIB, Open-label, Randomized, Multicenter
Study Evaluating the Effect on Serum Lipids Following a Switch to the Protease
Inhibitor (PI) Atazanavir in HIV-1 Infected Subjects Evidencing Virologic
Suppression on their First PI-Based Antiretroviral Therapy
A4311006 – A Phase 2, Randomized, Double-Blind, Dose-Ranging
Study of Capravirine (AG1549) in Combination with Kaletra and at Least 2
Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Have
Failed Antiretroviral Regimens Containing Protease Inhibitors, Nonnucleoside
Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase
Inhibitors
A4311022 - A Rollover Study for Subjects Continuing Treatment
with Open-Label Capravirine Who Were Enrolled in Study A4311006
MDX010-10 - A Phase I Open-Label, Dose-Escalation Study of
MDX-010 Administered Monthly as Immunotherapy in Patients with Human
Immunodeficiency Virus
GS-01-934 - A Phase 3, Randomized, Open-Label, Multicenter
Study of the Treatment of Antiretroviral-Naïve, HIV-1-Infected Subjects
Comparing Tenofovir Disproxil Fumarate and Emtricitabine in Combination with
Efavirenz Versus Combivir® (lamivudine/zidovudine) and Efavirenz
NV17751 - Observational Cohort Study of Pneumonia in Fuzeon-exposed and Non-exposed Patients
AI424103 – A Phase IIIB, Open-Label, Randomized, Multi-center
Study Comparing Antiviral Efficacy, Safety, and Effect on Serum Lipids of
Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, each in Combination with Tenofovir
and either Didanosine EC or Stavudine XR in HIV-1 Infected Subjects Receiving a
NNRTI-Containing HAART Regimen who are Experiencing their First Virologic
Failure
TNX-355.03 - A Phase 2, Multicenter, Randomized,
Double-Blinded, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal
Antibody TNX-355 with Optimized Background Therapy in Treatment-Experienced
Subjects Infected with HIV-1
TMC125-C223 – A randomized, controlled, partially blinded
Phase IIb dose finding trial of TMC125, in HIV-1 infected
subjects with documented genotypic evidence of resistance to currently
available NNRTIs and with at least three primary PI mutations
TMC125-C211 – An open-label trial of TMC125 in HIV-1 infected
subjects who were randomized to an active control arm of any sponsor-selected
TMC125 trial and either virologically failed or
completed the entire treatment period